Dr. Madduri on the Results of the CARTITUDE-1 Trial in Multiple Myeloma

Video

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the results of the phase Ib/II CARTITUDE-1 trial of the BCMA-directed CAR T-cell therapy JNJ-4528 in patients with heavily pretreated relapsed/refractory multiple myeloma.

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the results of the phase Ib/II CARTITUDE-1 trial of the BCMA-directed CAR T-cell therapy JNJ-4528 in patients with heavily pretreated relapsed/refractory multiple myeloma.

<<< View more from the 2019 ASH Annual Meeting

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
Damien Maura, PhD, a senior scientist at Voyager Therapeutics
© 2025 MJH Life Sciences

All rights reserved.